Helius Medical Technologies (HSDT) AI Stock Analysis

• Market Cap: $5.44M
• Dividend Yield: N/A
• Average Volume (3M): 297.64K
• Price to Earnings (P/E): ―
• Beta (1Y): -0.34
• Revenue Growth: -35.03%
• EPS Growth: 57.39%
• Country: US
• Employees: 21
• Sector: Healthcare
• Sector Strength: 40
• Industry: Medical - Devices
• EPS (TTM): -8.70
• Shares Outstanding: 676,000
• 10 Day Avg. Volume: 113,393
• 30 Day Avg. Volume: 297,644
• PEG Ratio: -0.10
• Price to Book (P/B): 43.39
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -4.80
• Enterprise Value/Market Cap: 10.00
• Enterprise Value/Revenue: 26.55
• Enterprise Value/Gross Profit: -372.81
• Enterprise Value/Ebitda: -1.01
• 1Y Price Target: $2.90
• Price Target Upside: -60.54% Downside
• Rating Consensus: Hold
• Number of Analyst Covering: 1

• Rating: 40 Underperform
• Price Target: $7.00 ▼(-4.76%Downside)

The overall score is primarily influenced by Helius Medical Technologies' weak financial performance and bearish technical indicators. While recent corporate actions to regain Nasdaq compliance are positive, they are not enough to offset the negative impact of ongoing financial difficulties and poor stock performance.

Positive Factors

Reimbursement Approval

UnitedHealthcare has approved reimbursement for the PoNS device, adding a second private payer to provide coverage.

Therapeutic Program Results

HSDT announced positive results from the PoNS Therapeutic Experience Program, or PoNSTEP, study for people with multiple sclerosis.

Negative Factors

CMS Decision Impact

The unfavorable CMS reimbursement decision remains a significant barrier, limiting access to a key patient population and dampening near-term US revenue potential.

Reimbursement Challenges

The ongoing reimbursement headwind continues to limit access to key patient populations and suppress near-term growth.

Revenue Performance

HSDT reported lower-than-expected 1Q25 revenue, as adoption of the PoNS device remains inconsistent.

Helius Medical Technologies Business Overview & Revenue Model

Company Description

Helius Medical Technologies (HSDT) is a neurotechnology company focused on the development, licensing, and commercialization of innovative treatments for neurological conditions. The company is engaged in the healthcare sector, specifically targeting treatments for balance and gait disorders. Its core product is the Portable Neuromodulation Stimulator (PoNS), a non-invasive medical device designed to improve balance and gait in patients with neurological diseases or trauma.

How the Company Makes Money

Helius Medical Technologies generates revenue primarily through the sale and licensing of its PoNS device. The company collaborates with healthcare providers, rehabilitation centers, and clinics to distribute its device to patients in need of balance and gait therapy. Additionally, Helius may enter into strategic partnerships or licensing agreements with other organizations to expand its market reach and enhance its product offerings, which can also contribute to its revenue streams. The company's earnings are influenced by factors such as regulatory approvals, clinical study outcomes, and the overall adoption of its technology in the medical community.

Helius Medical Technologies Financial Statement Overview

Summary

Helius Medical Technologies displays significant financial challenges, with declining revenue and consistent net losses. The company has a negative free cash flow and low profitability, indicating poor financial health and operational difficulties.

Income Statement

Helius Medical Technologies has shown declining revenue over recent years with a significant drop from $644,000 in 2023 to $520,000 in 2024. The company reports consistent net losses, with a net profit margin of -2257.69% in 2024. The EBIT and EBITDA margins are both negative, indicating operational difficulties. Revenue growth is negative, further reflecting the challenging business environment.

Balance Sheet

The company's balance sheet reveals a highly leveraged position with a debt-to-equity ratio of 0.01 in 2024, indicating minimal use of debt financing. However, stockholders' equity has decreased over time, reducing financial strength. The equity ratio is 29.89%, suggesting a moderate reliance on equity financing. Return on equity is negative due to consistent net losses.

Cash Flow

The cash flow statement indicates negative free cash flow of -$11,046,000 in 2024, signaling cash flow challenges. The operating cash flow to net income ratio is negative, reflecting poor cash generation from operations compared to net losses. Despite some financing cash inflows, the company struggles with cash outflows, impacting its liquidity position.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	520.00K	644.00K	787.00K	522.00K	661.00K
Gross Profit	-62.00K	61.00K	324.00K	224.00K	-90.00K
EBITDA	-13.80M	-12.11M	-14.50M	-17.82M	-13.65M
Net Income	-11.74M	-8.85M	-14.07M	-18.13M	-14.13M
Balance Sheet
Total Assets	3.54M	7.69M	17.29M	14.10M	6.55M
Cash, Cash Equivalents and Short-Term Investments	1.09M	5.18M	14.55M	11.01M	3.33M
Total Debt	12.00K	57.00K	110.00K	3.00K	91.00K
Total Liabilities	2.48M	5.34M	9.14M	2.85M	2.68M
Stockholders Equity	1.06M	2.35M	8.15M	11.26M	3.87M
Cash Flow
Free Cash Flow	-11.05M	-10.45M	-14.33M	-13.44M	-11.80M
Operating Cash Flow	-11.04M	-10.42M	-14.31M	-13.39M	-11.74M
Investing Cash Flow	-5.00K	-29.00K	-11.00K	-56.00K	-9.00K
Financing Cash Flow	6.95M	1.08M	17.87M	21.13M	9.64M

Helius Medical Technologies Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 7.35
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Positive
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HSDT, the sentiment is Negative. The current price of 7.35 is below the 20-day moving average (MA) of 12.91, below the 50-day MA of 109.89, and below the 200-day MA of 325.55, indicating a bearish trend. The MACD of -27.49 indicates Negative momentum. The RSI at 21.11 is Positive, neither overbought nor oversold. The STOCH value of 6.74 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HSDT.

Helius Medical Technologies Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	64 Neutral	¥344.41B	11.03	-2.99%	2.56%	11.77%	-10.16%
PAVM	54 Neutral	$10.16M	0.81	-499.57%	―	-33.92%	―
VVOS	53 Neutral	$40.17M	―	-450.47%	―	9.47%	81.37%
TIVC	43 Neutral	$3.92M	―	-218.77%	―	-33.67%	91.72%
SINT	42 Neutral	$7.45M	―	-155.20%	―	9.90%	94.56%
HSDT	40 Underperform	$5.44M	―	-800.00%	―	-35.03%	57.39%

Helius Medical Technologies Corporate Events

Helius Medical Regains Nasdaq Compliance

On July 7, 2025, Helius Medical Technologies announced that it has regained compliance with Nasdaq’s equity and minimum bid price requirements, ensuring its continued listing on The Nasdaq Capital Market. The company will be under a mandatory monitoring period until July 7, 2026, during which any further non-compliance could lead to a delisting determination without the opportunity for a compliance plan or additional time.

The most recent analyst rating on (HSDT) stock is a Buy with a $4.00 price target. To see the full list of analyst forecasts on Helius Medical Technologies stock, see the HSDT Stock Forecast page.

Helius Medical Files $25M Stock Offering Prospectus

On July 7, 2025, Helius Medical Technologies filed an updated Prospectus Supplement to offer and sell up to $25 million of its common stock through Roth Capital Partners. The proceeds from this offering are intended for working capital and general corporate purposes, including commercialization efforts and research and development activities.

The most recent analyst rating on (HSDT) stock is a Buy with a $4.00 price target. To see the full list of analyst forecasts on Helius Medical Technologies stock, see the HSDT Stock Forecast page.

Helius Medical Approves Reverse Stock Split Plan

On June 20, 2025, Helius Medical Technologies‘ Board of Directors approved a 1-for-50 reverse stock split of its Class A common stock, effective July 1, 2025, to meet Nasdaq’s listing requirements. This move will reduce the number of outstanding shares from approximately 33.8 million to 0.7 million, while the stock will continue trading under the symbol ‘HSDT’ on a split-adjusted basis starting July 1, 2025.

The most recent analyst rating on (HSDT) stock is a Buy with a $4.00 price target. To see the full list of analyst forecasts on Helius Medical Technologies stock, see the HSDT Stock Forecast page.

Helius Medical Raises $8.1M to Meet Nasdaq Compliance

Helius Medical Technologies, Inc. faced a compliance issue with Nasdaq’s minimum stockholders’ equity requirement after their equity fell below $2.5 million as of December 31, 2024. On June 6, 2025, the company completed a public offering raising approximately $8.1 million, which helped them meet the equity requirement. As of June 17, 2025, Helius Medical Technologies believes it has regained compliance and awaits Nasdaq’s confirmation for continued listing.

The most recent analyst rating on (HSDT) stock is a Buy with a $4.00 price target. To see the full list of analyst forecasts on Helius Medical Technologies stock, see the HSDT Stock Forecast page.

Helius Medical Expands Equity Plan Amid Share Increase

Helius Medical Technologies announced that its Board of Directors approved an amendment to the 2022 Equity Incentive Plan, increasing the number of shares of common stock by 20% of the Fully Diluted Shares. This amendment was approved by stockholders on May 23, 2025, and resulted in an increase to 7.1 million shares available under the plan as of June 16, 2025, following a public offering.

The most recent analyst rating on (HSDT) stock is a Buy with a $4.00 price target. To see the full list of analyst forecasts on Helius Medical Technologies stock, see the HSDT Stock Forecast page.

Helius Medical Technologies Achieves Nasdaq Bid Price Compliance

On June 3, 2025, Helius Medical Technologies received formal notification from Nasdaq confirming its compliance with the Nasdaq Listing Rule 5550(a)(2), which requires a minimum closing bid price of $1.00 per share. Despite this compliance, the company must still meet the equity requirement by June 30, 2025, to fulfill all Nasdaq listing criteria, keeping the Nasdaq Listing Qualifications hearing process open until then.

The most recent analyst rating on (HSDT) stock is a Buy with a $4.00 price target. To see the full list of analyst forecasts on Helius Medical Technologies stock, see the HSDT Stock Forecast page.

Helius Medical Approves Reverse Stock Split and Share Increase

At a special meeting on May 23, 2025, Helius Medical Technologies‘ stockholders approved several significant proposals, including a reverse stock split and an increase in authorized shares to 800 million. These decisions aim to ensure compliance with Nasdaq listing requirements and facilitate potential financing, impacting the company’s operational and strategic positioning.

The most recent analyst rating on (HSDT) stock is a Buy with a $4.00 price target. To see the full list of analyst forecasts on Helius Medical Technologies stock, see the HSDT Stock Forecast page.